PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
75.64
+0.20 (0.27%)
At close: Dec 12, 2025, 4:00 PM EST
77.14
+1.50 (1.98%)
After-hours: Dec 12, 2025, 7:35 PM EST
PTC Therapeutics Revenue
PTC Therapeutics had revenue of $211.01M in the quarter ending September 30, 2025, with 7.23% growth. This brings the company's revenue in the last twelve months to $1.78B, up 97.54% year-over-year. In the year 2024, PTC Therapeutics had annual revenue of $806.78M, down -13.97%.
Revenue (ttm)
$1.78B
Revenue Growth
+97.54%
P/S Ratio
3.33
Revenue / Employee
$1,894,728
Employees
939
Market Cap
6.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 806.78M | -131.04M | -13.97% |
| Dec 31, 2023 | 937.82M | 239.02M | 34.20% |
| Dec 31, 2022 | 698.80M | 160.21M | 29.75% |
| Dec 31, 2021 | 538.59M | 157.83M | 41.45% |
| Dec 31, 2020 | 380.77M | 73.79M | 24.04% |
| Dec 31, 2019 | 306.98M | 42.25M | 15.96% |
| Dec 31, 2018 | 264.73M | 70.34M | 36.19% |
| Dec 31, 2017 | 194.39M | 111.69M | 135.04% |
| Dec 31, 2016 | 82.71M | 45.94M | 124.95% |
| Dec 31, 2015 | 36.77M | 11.52M | 45.64% |
| Dec 31, 2014 | 25.25M | -9.45M | -27.24% |
| Dec 31, 2013 | 34.70M | 750.00K | 2.21% |
| Dec 31, 2012 | 33.95M | -71.47M | -67.80% |
| Dec 31, 2011 | 105.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PTCT News
- 8 days ago - PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 9 days ago - PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? - The Motley Fool
- 9 days ago - PTC Therapeutics, Inc. (PTCT) Discusses Progress in Small Molecule Splicing and Ferroptosis Platforms Transcript - Seeking Alpha
- 10 days ago - Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You? - The Motley Fool
- 11 days ago - PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 11 days ago - Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors - GlobeNewsWire
- 13 days ago - A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000 - The Motley Fool
- 18 days ago - Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600 - PRNewsWire